Favezelimab-pembrolizumab for treating metastatic PD-L1 positive colorectal cancer

Favezelimab-pembrolizumab is in development for adult patients with previously treated programme death ligand-1 positive (PD-L1+) metastatic colorectal cancer. Colorectal cancer, which is also called bowel cancer, is a type of cancer that starts from the large bowel (colon) and the back passage (rectum). Metastatic cancer is when the cancer has spread from where it started, elsewhere in the body. PD-L1+ means that there are proteins on the surface of the cancer cells which make it harder for the body to identify them and this can make the cancer harder to treat. Patients with PD-L1+ metastatic colorectal cancer have limited treatment options resulting in high mortality rates.